Page 1

Personalis Personalis Reports Second Quarter 2021 Financial Results August 4 , 2021 MENLO PARK , Calif .-- ( BUSINESS WIRE ) -- Aug . 4 , 2021 -- Personalis , Inc. ( Nasdaq : PSNL ) , a leader in advanced genomics for cancer and population sequencing , today reported financial results for the second quarter ended June 30 , 2021 . Second Quarter and Recent Highlights • Record quarterly revenue of $ 21.7 million in the second quarter of 2021 compared with $ 19.5 million in the second quarter of 2020 , an 11 % increase • Revenue of $ 8.2 million from biopharma and all other customers , excluding the U.S. Department of Veterans Affairs Million Veteran Program ( VA MVP ) , in the second quarter of 2021 compared with $ 4.7 million in the second quarter of 2020 , a 72 % increase • Ended the second quarter with cash , cash equivalents , and short - term investments of $ 328.9 million as of June 30 , 2021 • Achieved milestone of delivering more than 125,000 whole human genome sequences to the VA MVP " I'm proud to say that we were able to report record revenue once again this quarter and that we achieved our twentieth consecutive quarter of growth , as we converted an increasing number of orders into revenue . Revenue from biopharma and all other customers grew 72 % over the same period of the prior year , and increased sequentially for the seventh consecutive quarter , " said John West , Chief Executive Officer . " Recently , we achieved a significant milestone of sequencing our 125,000th whole human genome for the VA MVP , which highlights our expertise and ability to scale . In addition , our development efforts for NeXT Personal , our Minimal Residual Disease ( MRD ) offering that we expect to launch in 2021 , remain on - track . " Second Quarter 2021 Financial Results Revenue was $ 21.7 million in the three months ended June 30 , 2021 , up 11 % from $ 19.5 million in the same period of the prior year . Gross margin was 37.7 % in the three months ended June 30 , 2021 , compared with 24.0 % in the same period of the prior year . Operating expenses were $ 23.1 million in the three months ended June 30 , 2021 , compared with $ 14.2 million in the same period of the prior year . Net loss was $ 15.0 million in the three months ended June 30 , 2021 and net loss per share was $ 0.34 based on a weighted - average basic and diluted share count of 44.0 million , compared with a net loss of $ 9.3 million and a net loss per share of $ 0.29 on a weighted - average basic and diluted share count of 31.7 million in the same period of the prior year . Business Outlook Personalis expects the following for the third quarter of 2021 : • Total revenue to be approximately $ 22.2 million • Revenue from biopharma and all other customers , excluding VA MVP , to be in the range of $ 7.5 million to $ 8.5 million • Net Loss to be in the range of $ 17 million to $ 18 million ; estimated outstanding shares of 44 million Personalis expects the following for the full year of 2021 : • Total revenue to be approximately $ 85 million • Revenue from biopharma and all other customers , excluding VA MVP , to be in the range of $ 33 million to $ 34 million • Net Loss to be in the range of $ 65 million to $ 70 million ; estimated outstanding shares of 44 million Webcast and Conference Call Information Personalis will host a conference call to discuss the second quarter 2021 financial results after market close on Wednesday , August 4 , 2021 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time . The conference call can be accessed live over the phone by dialing ( 866 ) 220-8061 for U.S. callers or ( 470 ) 495-9168 for international callers , using the conference ID : 8564509. The live webinar can be accessed at https://investors.personalis.com . About Personalis , Inc. Personalis , Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics . The Personalis NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer , providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes , together with the immune system , from a single tissue sample . In population sequencing , Personalis operates one of the largest sequencing laboratories globally and is currently the sole sequencing provider to the VA MVP . To enable cancer and population sequencing , the Personalis Clinical Laboratory is built with a focus on clinical accuracy , quality , big data , scale , and efficiency . The laboratory is GxP aligned as well as CLIA88 - certified and CAP - accredited . For more information , please visit www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ) . Forward - Looking Statements